Insider transaction details
Malik Fady Ibraham, who serves as executive vice president of research and development at Cytokinetics Inc. (NASDAQ: CYTK), completed the sale of 3,500 shares of the company's common stock on April 21, 2026. The shares changed hands at $65.69 apiece, producing gross proceeds of $229,915.
The disposition followed an immediate acquisition of the same number of shares through the exercise of non-qualified stock options. Dr. Malik paid $7.80 per share when exercising those options, representing a total option exercise cost of $27,300.
After the option exercise and subsequent sale, Dr. Malik retains direct ownership of 153,902 shares of Cytokinetics common stock.
Analyst activity and company catalysts
Market attention around Cytokinetics has been elevated in parallel with these insider transactions. Several brokerages and research teams have either raised price targets or maintained positive ratings recently. Mizuho increased its target to $100, citing an extension of the intellectual property protection for aficamten through 2041 and raising its probability of success for the non-obstructive hypertrophic cardiomyopathy indication to 75%.
Evercore ISI reiterated an Outperform rating with a $80 target, pointing to potential value that could be realized if the forthcoming Phase 3 ACACIA trial produces favorable readouts. Stifel kept a Buy rating with a $98 target, assigning a 70% probability of success to ACACIA based on prior data.
JPMorgan raised its price target to $75, noting a constructive view following approval of Myqorzo for obstructive hypertrophic cardiomyopathy. Leerink Partners reiterated an Outperform rating and a price target of $84, citing confidence in the early U.S. launch of Myqorzo and anticipation of the Phase 3 ACACIA trial readout.
Collectively, these analyst actions reflect a positive tone from the sell side regarding Cytokinetics' strategy and financial outlook.
Additional resource note
For investors seeking further analysis of Cytokinetics' financials and insider trading patterns, InvestingPro is cited as offering comprehensive analysis with over 10 additional ProTips and detailed metrics intended to support investment decision-making.